Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence...

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Aug 25, 2021 at 9:52 PM.

  1. #1 cafead, Aug 25, 2021 at 9:52 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,028
    Likes Received:
    3
    via With real-world data in hand, the Institute for Clinical and Economic Review (ICER) is retooling its cost-effectiveness models for three rare disease drugs. And the new discounts it has in mind are steep.


    The meds in question—Takeda’s Takhzyro and Cinryze, plus CSL Behring’s Haegarda—all carry FDA approvals for long-term prevention of hereditary angioedema (HAE) attacks. Using real-world evidence (RWE) garnered with the help of Aetion and the University of Washington, ICER found patients suffered fewer baseline HAE attacks in the real world than investigators noticed in clinical studies.

    article source
     
    Quote

Reply to Thread